메뉴 건너뛰기




Volumn 15, Issue 5, 2013, Pages 445-449

Acute promyelocytic leukemia: Do we have a new front-line standard of treatment?

Author keywords

Acute promyelocytic leukemia; All trans retinoic acid; Anthracycline; Arsenic trioxide; Chemotherapy; Targeted therapy

Indexed keywords

ANTHRACYCLINE; ARSENIC TRIOXIDE; CYTARABINE; DAUNORUBICIN; DEXAMETHASONE; GEMTUZUMAB; IDARUBICIN; MERCAPTOPURINE; METHOTREXATE; OZOGAMICIN; RETINOIC ACID;

EID: 84884595287     PISSN: 15233790     EISSN: 15346269     Source Type: Journal    
DOI: 10.1007/s11912-013-0339-z     Document Type: Article
Times cited : (7)

References (32)
  • 1
    • 61949441174 scopus 로고    scopus 로고
    • Management of acute promyelocytic leukemia: Recommendations from an expert panel on behalf of the European LeukemiaNet
    • Comprehensive evidence- and expert opinion-based guidelines on the diagnosis and management of APL
    • •• Sanz MA, Grimwade D, Tallman MS, et al. Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood. 2009;113(9):1875-91. Comprehensive evidence- and expert opinion-based guidelines on the diagnosis and management of APL.
    • (2009) Blood , vol.113 , Issue.9 , pp. 1875-1891
    • Sanz, M.A.1    Grimwade, D.2    Tallman, M.S.3
  • 2
    • 0033566639 scopus 로고    scopus 로고
    • A randomized comparison of all transretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia
    • 10438706 1:CAS:528:DyaK1MXlt1Olurk%3D
    • Fenaux P, Chastang C, Chevret S, et al. A randomized comparison of all transretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. Blood. 1999;94(4):1192-200.
    • (1999) Blood , vol.94 , Issue.4 , pp. 1192-1200
    • Fenaux, P.1    Chastang, C.2    Chevret, S.3
  • 3
    • 0033230342 scopus 로고    scopus 로고
    • A modified AIDA protocol with anthracycline-based consolidation results in high antileukemic efficacy and reduced toxicity in newly diagnosed PML/RARα-positive acute promyelocytic leukemia
    • 10556184 1:CAS:528:DyaK1MXntVSrsbk%3D
    • Sanz MA, Martin G, Rayon C, et al. A modified AIDA protocol with anthracycline-based consolidation results in high antileukemic efficacy and reduced toxicity in newly diagnosed PML/RARα-positive acute promyelocytic leukemia. Blood. 1999;94(9):3015-21.
    • (1999) Blood , vol.94 , Issue.9 , pp. 3015-3021
    • Sanz, M.A.1    Martin, G.2    Rayon, C.3
  • 4
    • 0033564337 scopus 로고    scopus 로고
    • Presenting white blood cell count and kinetics of molecular remission predict prognosis in acute promyelocytic leukemia treated with all-trans retinoic acid: Result of the randomized MRC trial
    • 10361110 1:CAS:528:DyaK1MXjvVGrtrg%3D
    • Burnett AK, Grimwade D, Solomon E, Wheatley K, Goldstone AH. Presenting white blood cell count and kinetics of molecular remission predict prognosis in acute promyelocytic leukemia treated with all-trans retinoic acid: result of the randomized MRC trial. Blood. 1999;93(12):4131-43.
    • (1999) Blood , vol.93 , Issue.12 , pp. 4131-4143
    • Burnett, A.K.1    Grimwade, D.2    Solomon, E.3    Wheatley, K.4    Goldstone, A.H.5
  • 5
    • 10744220024 scopus 로고    scopus 로고
    • Risk-adapted treatment of acute promyelocytic leukemia with all-trans-retinoic acid and anthracycline monochemotherapy: A multicenter study by the PETHEMA group
    • 14576047 10.1182/blood-2003-07-2462 1:CAS:528:DC%2BD2cXhsVSlt7g%3D
    • Sanz MA, Martin G, Gonzalez M, et al. Risk-adapted treatment of acute promyelocytic leukemia with all-trans-retinoic acid and anthracycline monochemotherapy: a multicenter study by the PETHEMA group. Blood. 2004;103(4):1237-43.
    • (2004) Blood , vol.103 , Issue.4 , pp. 1237-1243
    • Sanz, M.A.1    Martin, G.2    Gonzalez, M.3
  • 6
    • 0030825408 scopus 로고    scopus 로고
    • Molecular remission in PML/RARα-positive acute promyelocytic leukemia by combined all-trans retinoic acid and idarubicin (AIDA) therapy
    • 9242531 1:CAS:528:DyaK2sXkvVWhtLs%3D
    • Mandelli F, Diverio D, Avvisati G, et al. Molecular remission in PML/RARα-positive acute promyelocytic leukemia by combined all-trans retinoic acid and idarubicin (AIDA) therapy. Blood. 1997;90(3):1014-21.
    • (1997) Blood , vol.90 , Issue.3 , pp. 1014-1021
    • Mandelli, F.1    Diverio, D.2    Avvisati, G.3
  • 7
    • 0031961755 scopus 로고    scopus 로고
    • Analysis of prognostic factors in newly diagnosed acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy. Japan Adult Leukemia Study Group
    • 9440726 1:CAS:528:DyaK1cXmtleqtA%3D%3D
    • Asou N, Adachi K, Tamura J, et al. Analysis of prognostic factors in newly diagnosed acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy. Japan Adult Leukemia Study Group. J Clin Oncol. 1998;16(1):78-85.
    • (1998) J Clin Oncol , vol.16 , Issue.1 , pp. 78-85
    • Asou, N.1    Adachi, K.2    Tamura, J.3
  • 8
    • 0033858433 scopus 로고    scopus 로고
    • Double induction strategy including high dose cytarabine in combination with all-trans retinoic acid: Effects in patients with newly diagnosed acute promyelocytic leukemia
    • 10942230 10.1038/sj.leu.2401843 1:CAS:528:DC%2BD3cXmtFOiu7k%3D
    • Lengfelder E, Reichert A, Schoch C, et al. Double induction strategy including high dose cytarabine in combination with all-trans retinoic acid: effects in patients with newly diagnosed acute promyelocytic leukemia. Leukemia. 2000;14(8):1362-70.
    • (2000) Leukemia , vol.14 , Issue.8 , pp. 1362-1370
    • Lengfelder, E.1    Reichert, A.2    Schoch, C.3
  • 9
    • 84876036212 scopus 로고    scopus 로고
    • Improving acute promyelocytic leukemia (APL) outcome in developing countries through networking, results of the International Consortium on APL
    • 23319575 10.1182/blood-2012-08-449918 1:CAS:528:DC%2BC3sXkvVGjt7w%3D
    • Rego EM, Kim HT, Ruiz-Arguelles GJ, et al. Improving acute promyelocytic leukemia (APL) outcome in developing countries through networking, results of the International Consortium on APL. Blood. 2013;121(11):1935-43.
    • (2013) Blood , vol.121 , Issue.11 , pp. 1935-1943
    • Rego, E.M.1    Kim, H.T.2    Ruiz-Arguelles, G.J.3
  • 10
    • 77958456360 scopus 로고    scopus 로고
    • Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710
    • 20705755 10.1182/blood-2010-02-269621 1:CAS:528:DC%2BC3cXhsFahsLfL
    • Powell BL, Moser B, Stock W, et al. Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710. Blood. 2010;116(19):3751-7.
    • (2010) Blood , vol.116 , Issue.19 , pp. 3751-3757
    • Powell, B.L.1    Moser, B.2    Stock, W.3
  • 11
    • 77958499078 scopus 로고    scopus 로고
    • Front-line treatment of acute promyelocytic leukemia with AIDA induction followed by risk-adapted consolidation for adults younger than 61 years: Results of the AIDA-2000 trial of the GIMEMA group
    • 20644121 10.1182/blood-2010-03-276196 1:CAS:528:DC%2BC3cXhsVeisLvP
    • Lo-Coco F, Avvisati G, Vignetti M, et al. Front-line treatment of acute promyelocytic leukemia with AIDA induction followed by risk-adapted consolidation for adults younger than 61 years: results of the AIDA-2000 trial of the GIMEMA group. Blood. 2010;116(17):3171-9.
    • (2010) Blood , vol.116 , Issue.17 , pp. 3171-3179
    • Lo-Coco, F.1    Avvisati, G.2    Vignetti, M.3
  • 12
    • 77954681398 scopus 로고    scopus 로고
    • Risk-adapted treatment of acute promyelocytic leukemia based on all-trans retinoic acid and anthracycline with addition of cytarabine in consolidation therapy for high-risk patients: Further improvements in treatment outcome
    • 20393132 10.1182/blood-2010-01-266007 1:CAS:528:DC%2BC3cXovVWlt7g%3D
    • Sanz MA, Montesinos P, Rayon C, et al. Risk-adapted treatment of acute promyelocytic leukemia based on all-trans retinoic acid and anthracycline with addition of cytarabine in consolidation therapy for high-risk patients: further improvements in treatment outcome. Blood. 2010;115(25):5137-46.
    • (2010) Blood , vol.115 , Issue.25 , pp. 5137-5146
    • Sanz, M.A.1    Montesinos, P.2    Rayon, C.3
  • 13
    • 0842328527 scopus 로고    scopus 로고
    • Clinico-biological features and outcome of acute promyelocytic leukemia patients with persistent polymerase chain reaction-detectable disease after the AIDA front-line induction and consolidation therapy
    • 14754603
    • Breccia M, Diverio D, Noguera NI, et al. Clinico-biological features and outcome of acute promyelocytic leukemia patients with persistent polymerase chain reaction-detectable disease after the AIDA front-line induction and consolidation therapy. Haematologica. 2004;89(1):29-33.
    • (2004) Haematologica , vol.89 , Issue.1 , pp. 29-33
    • Breccia, M.1    Diverio, D.2    Noguera, N.I.3
  • 14
    • 38949092914 scopus 로고    scopus 로고
    • Treatment of newly diagnosed acute promyelocytic leukemia (APL): A comparison of French-Belgian-Swiss and PETHEMA results
    • 17975017 10.1182/blood-2007-07-099978 1:CAS:528:DC%2BD1cXhvFejsb0%3D
    • Ades L, Sanz MA, Chevret S, et al. Treatment of newly diagnosed acute promyelocytic leukemia (APL): a comparison of French-Belgian-Swiss and PETHEMA results. Blood. 2008;111(3):1078-84.
    • (2008) Blood , vol.111 , Issue.3 , pp. 1078-1084
    • Ades, L.1    Sanz, M.A.2    Chevret, S.3
  • 15
    • 77949889670 scopus 로고    scopus 로고
    • Single cycle of arsenic trioxide-based consolidation chemotherapy spares anthracycline exposure in the primary management of acute promyelocytic leukemia
    • 20085935 10.1200/JCO.2009.25.5158 1:CAS:528:DC%2BC3cXktF2ltrc%3D
    • Gore SD, Gojo I, Sekeres MA, et al. Single cycle of arsenic trioxide-based consolidation chemotherapy spares anthracycline exposure in the primary management of acute promyelocytic leukemia. J Clin Oncol. 2010;28(6):1047-53.
    • (2010) J Clin Oncol , vol.28 , Issue.6 , pp. 1047-1053
    • Gore, S.D.1    Gojo, I.2    Sekeres, M.A.3
  • 16
    • 34247369329 scopus 로고    scopus 로고
    • Is cytarabine useful in the treatment of acute promyelocytic leukemia? Results of a randomized trial from the European Acute Promyelocytic Leukemia Group
    • 17116939 10.1200/JCO.2006.08.1596 1:CAS:528:DC%2BD2sXhtVChs7Y%3D
    • Ades L, Chevret S, Raffoux E, et al. Is cytarabine useful in the treatment of acute promyelocytic leukemia? Results of a randomized trial from the European Acute Promyelocytic Leukemia Group. J Clin Oncol. 2006;24(36):5703-10.
    • (2006) J Clin Oncol , vol.24 , Issue.36 , pp. 5703-5710
    • Ades, L.1    Chevret, S.2    Raffoux, E.3
  • 17
    • 9444297295 scopus 로고    scopus 로고
    • All-trans retinoic acid and anthracycline monochemotherapy for the treatment of elderly patients with acute promyelocytic leukemia
    • 15292063 10.1182/blood-2004-04-1642 1:CAS:528:DC%2BD2cXhtVGltLfK
    • Sanz MA, Vellenga E, Rayon C, et al. All-trans retinoic acid and anthracycline monochemotherapy for the treatment of elderly patients with acute promyelocytic leukemia. Blood. 2004;104(12):3490-3.
    • (2004) Blood , vol.104 , Issue.12 , pp. 3490-3493
    • Sanz, M.A.1    Vellenga, E.2    Rayon, C.3
  • 18
    • 0038378897 scopus 로고    scopus 로고
    • Treatment of elderly patients (> or =60 years) with newly diagnosed acute promyelocytic leukemia. Results of the Italian multicenter group GIMEMA with ATRA and idarubicin (AIDA) protocols
    • 12764372 10.1038/sj.leu.2402932 1:CAS:528:DC%2BD3sXjvFKjtrY%3D
    • Mandelli F, Latagliata R, Avvisati G, et al. Treatment of elderly patients (> or =60 years) with newly diagnosed acute promyelocytic leukemia. Results of the Italian multicenter group GIMEMA with ATRA and idarubicin (AIDA) protocols. Leukemia. 2003;17(6):1085-90.
    • (2003) Leukemia , vol.17 , Issue.6 , pp. 1085-1090
    • Mandelli, F.1    Latagliata, R.2    Avvisati, G.3
  • 19
    • 0041828184 scopus 로고    scopus 로고
    • Treatment of older adults with acute promyelocytic leukaemia
    • 12935965 10.1016/S1521-6926(03)00044-6 1:CAS:528:DC%2BD3sXmsVCnsr4%3D
    • Fenaux P, Chevret S, de Botton S. Treatment of older adults with acute promyelocytic leukaemia. Best Pract Res Clin Haematol. 2003;16(3):495-501.
    • (2003) Best Pract Res Clin Haematol , vol.16 , Issue.3 , pp. 495-501
    • Fenaux, P.1    Chevret, S.2    De Botton, S.3
  • 20
    • 54049087434 scopus 로고    scopus 로고
    • Risk-adapted treatment of acute promyelocytic leukemia with all-trans retinoic acid and anthracycline monochemotherapy: Long-term outcome of the LPA 99 multicenter study by the PETHEMA Group
    • 18664623 10.1182/blood-2008-05-159632 1:CAS:528:DC%2BD1cXht1Omur7L
    • Sanz MA, Montesinos P, Vellenga E, et al. Risk-adapted treatment of acute promyelocytic leukemia with all-trans retinoic acid and anthracycline monochemotherapy: long-term outcome of the LPA 99 multicenter study by the PETHEMA Group. Blood. 2008;112(8):3130-4.
    • (2008) Blood , vol.112 , Issue.8 , pp. 3130-3134
    • Sanz, M.A.1    Montesinos, P.2    Vellenga, E.3
  • 21
    • 0034663162 scopus 로고    scopus 로고
    • Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: A joint study of the PETHEMA and GIMEMA cooperative groups
    • 10942364 1:CAS:528:DC%2BD3cXlvF2it7s%3D
    • Sanz MA, Lo Coco F, Martin G, et al. Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: a joint study of the PETHEMA and GIMEMA cooperative groups. Blood. 2000;96(4):1247-53.
    • (2000) Blood , vol.96 , Issue.4 , pp. 1247-1253
    • Sanz, M.A.1    Lo Coco, F.2    Martin, G.3
  • 22
    • 68949137224 scopus 로고    scopus 로고
    • Prospective minimal residual disease monitoring to predict relapse of acute promyelocytic leukemia and to direct pre-emptive arsenic trioxide therapy
    • 19506161 10.1200/JCO.2008.20.1533 1:CAS:528:DC%2BD1MXhtVOnu7bO
    • Grimwade D, Jovanovic JV, Hills RK, et al. Prospective minimal residual disease monitoring to predict relapse of acute promyelocytic leukemia and to direct pre-emptive arsenic trioxide therapy. J Clin Oncol. 2009;27(22):3650-8.
    • (2009) J Clin Oncol , vol.27 , Issue.22 , pp. 3650-3658
    • Grimwade, D.1    Jovanovic, J.V.2    Hills, R.K.3
  • 23
    • 0033214651 scopus 로고    scopus 로고
    • Therapy of molecular relapse in acute promyelocytic leukemia
    • 10498592 1:CAS:528:DyaK1MXmsVCisL4%3D
    • Lo Coco F, Diverio D, Avvisati G, et al. Therapy of molecular relapse in acute promyelocytic leukemia. Blood. 1999;94(7):2225-9.
    • (1999) Blood , vol.94 , Issue.7 , pp. 2225-2229
    • Lo Coco, F.1    Diverio, D.2    Avvisati, G.3
  • 24
    • 33847178763 scopus 로고    scopus 로고
    • Outcome of patients with acute promyelocytic leukemia failing to front-line treatment with all-trans retinoic acid and anthracycline-based chemotherapy (PETHEMA protocols LPA96 and LPA99): Benefit of an early intervention
    • 17205057 10.1038/sj.leu.2404501 1:CAS:528:DC%2BD2sXhvFWks7Y%3D
    • Esteve J, Escoda L, Martin G, et al. Outcome of patients with acute promyelocytic leukemia failing to front-line treatment with all-trans retinoic acid and anthracycline-based chemotherapy (PETHEMA protocols LPA96 and LPA99): benefit of an early intervention. Leukemia. 2007;21(3):446-52.
    • (2007) Leukemia , vol.21 , Issue.3 , pp. 446-452
    • Esteve, J.1    Escoda, L.2    Martin, G.3
  • 25
    • 0030923479 scopus 로고    scopus 로고
    • All-trans-retinoic acid in acute promyelocytic leukemia
    • 9321529 10.1056/NEJM199710093371501 1:STN:280:DyaK2svkvFSluw%3D%3D
    • Tallman MS, Andersen JW, Schiffer CA, et al. All-trans-retinoic acid in acute promyelocytic leukemia. N Engl J Med. 1997;337(15):1021-8.
    • (1997) N Engl J Med , vol.337 , Issue.15 , pp. 1021-1028
    • Tallman, M.S.1    Andersen, J.W.2    Schiffer, C.A.3
  • 26
    • 79955991053 scopus 로고    scopus 로고
    • AIDA 0493 protocol for newly diagnosed acute promyelocytic leukemia: Very long-term results and role of maintenance
    • 21385856 10.1182/blood-2010-08-302950 1:CAS:528:DC%2BC3MXmsVWmsr4%3D
    • Avvisati G, Lo-Coco F, Paoloni FP, et al. AIDA 0493 protocol for newly diagnosed acute promyelocytic leukemia: very long-term results and role of maintenance. Blood. 2011;117(18):4716-25.
    • (2011) Blood , vol.117 , Issue.18 , pp. 4716-4725
    • Avvisati, G.1    Lo-Coco, F.2    Paoloni, F.P.3
  • 27
    • 34347386848 scopus 로고    scopus 로고
    • A randomized study with or without intensified maintenance chemotherapy in patients with acute promyelocytic leukemia who have become negative for PML-RARα transcript after consolidation therapy: The Japan Adult Leukemia Study Group (JALSG) APL97 study
    • 17374742 10.1182/blood-2006-08-043992 1:CAS:528:DC%2BD2sXnsVais7w%3D
    • Asou N, Kishimoto Y, Kiyoi H, et al. A randomized study with or without intensified maintenance chemotherapy in patients with acute promyelocytic leukemia who have become negative for PML-RARα transcript after consolidation therapy: the Japan Adult Leukemia Study Group (JALSG) APL97 study. Blood. 2007;110(1):59-66.
    • (2007) Blood , vol.110 , Issue.1 , pp. 59-66
    • Asou, N.1    Kishimoto, Y.2    Kiyoi, H.3
  • 28
    • 11144355810 scopus 로고    scopus 로고
    • 3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia
    • 15044693 10.1073/pnas.0400053101 1:CAS:528:DC%2BD2cXjsVagt74%3D
    • 3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci U S A. 2004;101(15):5328-35.
    • (2004) Proc Natl Acad Sci U S A , vol.101 , Issue.15 , pp. 5328-5335
    • Shen, Z.X.1    Shi, Z.Z.2    Fang, J.3
  • 29
    • 29844442869 scopus 로고    scopus 로고
    • Treatment of acute promyelocytic leukemia with arsenic trioxide without ATRA and/or chemotherapy
    • 16227315 10.1093/annonc/mdj019 1:STN:280:DC%2BD2MnntFKiug%3D%3D
    • Ghavamzadeh A, Alimoghaddam K, Ghaffari SH, et al. Treatment of acute promyelocytic leukemia with arsenic trioxide without ATRA and/or chemotherapy. Ann Oncol. 2006;17(1):131-4.
    • (2006) Ann Oncol , vol.17 , Issue.1 , pp. 131-134
    • Ghavamzadeh, A.1    Alimoghaddam, K.2    Ghaffari, S.H.3
  • 30
    • 33645498328 scopus 로고    scopus 로고
    • Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: Durable remissions with minimal toxicity
    • 16352810 10.1182/blood-2005-08-3532 1:CAS:528:DC%2BD28XjtlKltbs%3D
    • Mathews V, George B, Lakshmi KM, et al. Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: durable remissions with minimal toxicity. Blood. 2006;107(7):2627-32.
    • (2006) Blood , vol.107 , Issue.7 , pp. 2627-2632
    • Mathews, V.1    George, B.2    Lakshmi, K.M.3
  • 31
    • 33646386643 scopus 로고    scopus 로고
    • Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia
    • 16373661 10.1182/blood-2005-10-4006 1:CAS:528:DC%2BD28Xkt1Git7c%3D
    • Estey E, Garcia-Manero G, Ferrajoli A, et al. Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia. Blood. 2006;107(9):3469-73.
    • (2006) Blood , vol.107 , Issue.9 , pp. 3469-3473
    • Estey, E.1    Garcia-Manero, G.2    Ferrajoli, A.3
  • 32
    • 84880287051 scopus 로고    scopus 로고
    • Retinoic acid and arsenic trioxide for acute promyelocytic leukemia
    • 23841729 10.1056/NEJMoa1300874 1:CAS:528:DC%2BC3sXht1ejsb7K
    • Lo-Coco F, Avvisati G, Vignetti M, et al. Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. N Engl J Med. 2013;369(2):111-21.
    • (2013) N Engl J Med , vol.369 , Issue.2 , pp. 111-121
    • Lo-Coco, F.1    Avvisati, G.2    Vignetti, M.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.